Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CKD-519 in Healthy Volunteers
NCT03210649Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rocacetrapib in dyslipidemia (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Maximum Plasma Concentration at Day 14. Started Mar 2017; status: completed.
02
Drugs
rocacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03210649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210649.